Keywords: EMEA, Fabry disease, Genzyme, Fabrazyme, Replagal, Shire, Daytrana, ADHA

EMEA recommends Replagal as alternative Fabry treatment due to Fabrazyme shortage; FDA approves Shire’s Daytrana for adolescents

Article | 07 July 2010

Print This

The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) said yesterday that it has been obliged ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in